Out-licensing 'should be means to an end', not final goal

Mabwell, the first Chinese biotech company to complete an A-to-H share listing under Hong Kong's Chapter 18A biotech regime, believes out-licensing deals should be viewed primarily as a financing tool rather than the ultimate objective for China's innovative drugmakers, Chairman and CEO Liu Datao told China Daily.

Raccontata daglobal.chinadaily.com.cn